Pilot Trial Establishes Feasibility of Epigenetic Aging Biomarkers in Dietary Geroscience

A pilot trial in 34 adults with metabolic syndrome demonstrated that integrating epigenetic biological age assessments into dietary studies is highly feasible and strongly engages participants, despite no statistically significant epigenetic changes observed over the short 4-week duration.

Researchers conducted a prospective, longitudinal pilot study (NCT04361617) involving 34 adults aged 48–81 years with metabolic syndrome to evaluate the integration of DNA methylation-based biological age biomarkers into clinical dietary interventions.

Participants were assigned to consume 1 oz of tree nuts and two tablespoons of extra virgin olive oil daily for 4 weeks.

The study achieved a 97% retention rate (33 out of 34 participants completing the trial) and reported high dietary adherence exceeding 95% (98.6% mean adherence for nuts and 96.4% for olive oil).

At baseline, 100% of participants exhibited advanced biological aging as assessed by DunedinPACE, with a mean rate of 1.18 years of biological aging per chronological year.

No statistically significant changes in epigenetic aging metrics (DunedinPACE and AgeAccelGrim) or clinical metabolic syndrome parameters were observed over the 4-week intervention period.

The baseline findings confirm that individuals with metabolic syndrome represent a highly suitable target population for geroscience interventions due to their consistently accelerated rate of physiological decline.

Qualitative assessments showed that epigenetic feedback is a strong driver of patient compliance: 77% of participants highly desired knowing their biological age, and 82% stated that evidence of advanced aging would increase their motivation to stick to dietary interventions.

The study highlights functional differences in geroscience metrics, demonstrating that DunedinPACE, which tracks the immediate pace of physiological decline, is more closely aligned with metabolic risks than cumulative mortality clocks like GrimAge.

The study provides essential pilot data on biomarker variability, adherence rates, and trial feasibility to inform sample size and power calculations for future longer-term dietary geroscience studies.

The high participant interest in personalized biological aging feedback supports commercial models that combine continuous metabolic monitoring or diagnostics with consumer-facing biological age reporting to drive retention.

The initiation of larger, longer-term (3 to 4 years) clinical trials specifically powered to evaluate whether sustained dietary interventions can slow biological aging and improve healthspan in metabolic syndrome cohorts.